Kronos Bio Inc (NAS:KRON)
$ 1.01 -0.07 (-6.48%) Market Cap: 60.70 Mil Enterprise Value: -60.21 Mil PE Ratio: 0 PB Ratio: 0.44 GF Score: 33/100

Kronos Bio Inc at Goldman Sachs Healthcare Conference Transcript

Jun 15, 2023 / 05:40PM GMT
Release Date Price: $1.7 (+4.94%)
Salveen Richter
Goldman Sachs - Analyst

Great. Good morning, everyone. Thanks for joining us. Really pleased to have with us the Kronos team. We have Norbert Bischofberger, President and CEO; Yasir Al-Wakeel, CFO and Head of Corporate Development; and Jorge DiMartino --

Charles Lin
Kronos Bio, Inc. - SVP, Biology

I'm Charles.

Salveen Richter
Goldman Sachs - Analyst

Actually, Charles -- sorry. Charles, SVP of Biology.

Charles Lin
Kronos Bio, Inc. - SVP, Biology

Jorge couldn't make it.

Questions & Answers

Salveen Richter;Norbert Bischofberger
Goldman Sachs - Analyst;Kronos Bio, Inc. - President, CEO,

Yes. So maybe to start here, maybe 0742, your CDK inhibitor. It's the first molecule to emerge from your platform. Can you start by walking through the key takeaways for the first -- from the first data release that you provided as well as the rationale for your Phase 2 dose selection?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot